NCT06664021 2025-01-10
Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma
Anhui Provincial Hospital
Phase 2 Recruiting
Clinical Trials
8 trialsNCT03457337 2020-07-10
S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC
Henan Cancer Hospital
Phase 2 Unknown
NCT03397199 2020-04-15
Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT03950141 2019-05-15
Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer
Beijing Hospital
Phase 2 Unknown
NCT03137004 2017-05-08
Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT00980603 2009-09-21
Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer
National Cancer Center, Korea
Phase 2 Unknown
NCT00580359 2008-01-08
S-1 vs Capecitabine in the Elderly and/or Poor Performance Status Patients With Recurrent or Metastatic Gastric Cancer
National Cancer Center, Korea
Phase 2 Unknown
NCT00506571 2007-07-25
TIROX2
National Cancer Center, Korea
Phase 2 Unknown